Developers of Russian Sputnik V vaccine doubt EU regulator's neutrality, want apology
- Wall Street rebounds after two-day decline; Netflix slides
- Netflix (NFLX) Plunges Following Q1 Sub Miss, But One Analyst Sees Chance to Turn Bullish
- Oil prices drop 2% on U.S. crude build, COVID-19 surge in India
- Intuitive Surgical (ISRG) Q1 Beat Prompts Two Street Upgrades
- U.S. dollar losses bounce after Canada tips toward higher rates
FILE PHOTO: A medical worker holds a syringe with Sputnik V vaccine against the coronavirus disease (COVID-19) at a vaccination centre in Saint Petersburg, Russia February 24, 2021. REUTERS/Anton Vaganov
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
MOSCOW (Reuters) - The developers of Russia's Sputnik V vaccine against COVID-19 on Tuesday questioned the European Medicines Agency's (EMA) neutrality, after an official with the regulator urged EU states to refrain from approving the shot for now.
EMA management board chief Christa Wirthumer-Hoche told an Austrian talk show on Sunday that she would advise European Union countries against granting Sputnik V national emergency authorisation while EMA was still reviewing its safety and effectiveness.
"We demand a public apology from EMA's Christa Wirthumer-Hoche for her negative comments..., (which) raise serious questions about possible political interference in the ongoing EMA review," the developers wrote on the official Sputnik V Twitter account.
In a written response, the Amsterdam-headquartered EMA said its review process for possible vaccines makes sure that all EU countries have "access to effectively evaluated medicines at the same time and ensures centralised safety monitoring across their life cycle."
EMA said this month it would review data from ongoing trials of the vaccine until there was enough evidence for a formal marketing authorisation application.
Kremlin spokesman Dmitry Peskov called Wirthumer-Hoche's statement regrettable and inappropriate.
The developers said Sputnik V had already been authorised by 46 countries.
It has been approved or is being assessed for approval in three EU member states - Hungary, Slovakia and the Czech Republic - and EU officials have said Brussels could start negotiations with a vaccine maker if at least four member countries request it.
Sputnik V could be manufactured for the first time in Europe outside Russia after a deal to produce it in Italy was signed by the Moscow-based RDIF sovereign wealth fund and Swiss-based pharmaceutical company Adienne.
(Reporting by Gabrielle Tétrault-Farber; Additional reporting by Dmitry Antonov in Moscow and by Bart Meijer in Amsterdam; Editing by Andrew Osborn and John Stonestreet/Mark Heinrich)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DraftKings (DKNG) Names Gisele Bundchen as Special Advisor to the CEO and Board for ESG Initiatives
- Search for missing Indonesian submarine enters second day as neighbours offer help
- Millions face hunger as Myanmar crisis worsens, United Nations says